ReviewAmerican journal of cancer research2018
The role of adrenergic receptors in lung cancer.
Review in American journal of cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Neural regulation in lung cancer: from mechanisms to new therapeutic perspectives.Clinical and experimental medicine · 2026Review
- Immuno-oncological effects of the α2-adrenoceptor agonist dexmedetomidine.Oncoimmunology · 2025Article
- Nicotine-Induced VEGF Levels in NSCLC Cells Are Modulated by PKA, Hyaluronan, and p53.International journal of molecular sciences · 2025Article
- Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy.Drug delivery and translational research · 2025Review
- β-Adrenoceptors in Cancer: Old Players and New Perspectives.Handbook of experimental pharmacology · 2024Review
- Article
- Regulation of Soluble E-Cadherin Signaling in Non-Small-Cell Lung Cancer Cells by Nicotine, BDNF, and β-Adrenergic Receptor Ligands.Biomedicines · 2023Article
- Factor-specific generative pattern from large-scale drug-induced gene expression profile.Scientific reports · 2023Article
- Data-Driven Radiogenomic Approach for Deciphering Molecular Mechanisms Underlying Imaging Phenotypes in Lung Adenocarcinoma: A Pilot Study.International journal of molecular sciences · 2023Article
- Influence of Perioperative Anesthesia on Cancer Recurrence: from Basic Science to Clinical Practice.Current oncology reports · 2023Review
- ADRB2 Regulates the Proliferation and Metastasis of Gastrointestinal Stromal Tumor Cells by Enhancing the ETV1-c-KIT Signaling.Journal of oncology · 2023Article
- Understanding and modeling nerve-cancer interactions.Disease models & mechanisms · 2023Review
- ADRB2 expression predicts the clinical outcomes and is associated with immune cells infiltration in lung adenocarcinoma.Scientific reports · 2022Article
- Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors.Cell death discovery · 2022Article
- The molecular mechanism of chronic stress affecting the occurrence and development of breast cancer and potential drug therapy.Translational oncology · 2022Review
- Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.Frontiers in immunology · 2022Article
- The role of ADRB2 gene polymorphisms in malignancies.Molecular biology reports · 2021Review
- Anesthesia Techniques and Long-Term Oncological Outcomes.Frontiers in oncology · 2021Review
- Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.Journal of clinical medicine · 2020Article
- Glycosylation and raft endocytosis in cancer.Cancer metastasis reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenergic receptors (ARs), especially β-ARs, are constitutively expressed in most mammalian cells and are associated with various malignancies including lung cancer. Epidemiologic studies have reported that activation of β-AR signalling promotes the development and progression of lung cancer and that pharmacological interference by β-AR blockers could partially reverse lung cancer progression. In this review, we mainly focus on the role of β-ARs in lung cancer and then reveal the possible application of AR blockers in anti-tumour therapy for lung cancer.
Indexed as
Identifiers
30555740PMC6291649W2980803617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.